| 6.885 -0.185 (-2.62%) | 11-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.82 | 1-year : | 13.1 |
| Resists | First : | 9.26 | Second : | 11.22 |
| Pivot price | 8.45  |
|||
| Supports | First : | 6.09 | Second : | 5.07 |
| MAs | MA(5) : | 7.11 |
MA(20) : | 8.88 |
| MA(100) : | 9.04 |
MA(250) : | 14.18 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 19.1  |
D(3) : | 15 |
| RSI | RSI(14): 27.5 |
|||
| 52-week | High : | 46.79 | Low : | 3.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALGS ] has closed above bottom band by 17.0%. Bollinger Bands are 88% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.31 - 7.37 | 7.37 - 7.41 |
| Low: | 6.56 - 6.63 | 6.63 - 6.67 |
| Close: | 6.8 - 6.9 | 6.9 - 6.97 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Mon, 10 Nov 2025
Aligos Therapeutics (ALGS) Showcases Promising Data at AASLD 202 - GuruFocus
Mon, 10 Nov 2025
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025 - The Manila Times
Mon, 10 Nov 2025
Aligos Therapeutics (Nasdaq: ALGS) posts 100% - Stock Titan
Fri, 07 Nov 2025
Aligos Therapeutics Reports Q3 2025 Progress and Financials - TipRanks
Thu, 06 Nov 2025
Aligos Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary - TradingView
Thu, 06 Nov 2025
Aligos Therapeutics Q3 2025 Earnings: EPS Misses at $(3.04), Rev - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 3e+006 (%) |
| Held by Institutions | 10.3 (%) |
| Shares Short | 292 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.756e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 924 % |
| Return on Equity (ttm) | -40.3 % |
| Qtrly Rev. Growth | 3.17e+006 % |
| Gross Profit (p.s.) | -3.25 |
| Sales Per Share | -31.68 |
| EBITDA (p.s.) | -2.09783e+007 |
| Qtrly Earnings Growth | -13.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -75 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.22 |
| Price to Cash Flow | 1.15 |
| Dividend | 0 |
| Forward Dividend | 235000 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|